Toni Choueiri, MD, and Rohit Gosain, MD present 3-year follow-up data from the CheckMate 9ER trial, discussing a variety of outcomes concerning the use of nivolumab plus cabozantinib in patients with advanced renal cell carcinoma, and sharing clinical insights for community oncologists.
EP. 1: Overview of ccRCC and Introduction to the CheckMate 9ER TrialMay 1st 2023
Toni Choueiri, MD, and Rohit Gosain, MD share their clinical experience treating patients with clear cell renal cell carcinoma (ccRCC) and provide a short summary of previously reported data from the CheckMate 9ER trial.
EP. 2: A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER TrialMay 1st 2023
Drs Choueiri and Gosain review study design, patient demographics, and clinical characteristics from the CheckMate 9ER trial, including prior nephrectomy and PD-L1 status.
EP. 3: CheckMate 9ER: Progression-free Survival, Overall Survival, and ObjectiveMay 8th 2023
Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.
EP. 4: Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCCMay 8th 2023
Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.
EP. 5: A Post-hoc Analysis of CheckMate 9ER Data and Study ConclusionsMay 22nd 2023
A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.
EP. 6: Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCCMay 22nd 2023
Toni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.